Saturday 17 October 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
156.19
1.18
−0.75%
Follow GILD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
17.02 | 17.92 | 18.78 | 0.00 |
P/S ratio |
4.74 | 5.19 | 5.82 | 5.16 | |
P/FCF ratio |
15.06 | 16.15 | 16.92 | 12.13 | |
P/Operating CF |
33.59 | 45.89 | 68.04 | 43.95 | |
P/B ratio |
6.43 | 6.75 | 7.39 | 13.37 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.35 | 5.77 | 6.31 | 5.91 | |
EV/EBITDA |
11.74 | 13.30 | 14.30 | 687.43 | |
EV/Operating CF |
16.09 | 16.97 | 17.36 | 13.29 | |
EV/FCF |
16.98 | 17.98 | 18.34 | 13.92 | |
Quick Ratio |
1.01 | 1.06 | 1.31 | 0.75 | |
Current Ratio |
1.45 | 1.55 | 1.97 | 1.27 | |
Net Debt/EBITDA |
4.38 | 6.48 | 4.44 | (2.38) | |
Debt/Assets |
42.61% | 42.25% | 39.40% | 53.17% | |
Debt/Equity |
1.16 | 1.10 | 0.95 | 2.23 | |
Asset Turnover |
0.51 | 0.50 | 0.53 | 0.58 | |
Operating CF/Net income |
1.35 | 1.52 | 1.26 | (0.34) | |
Capex/Depreciation |
(0.21) | (0.30) | (0.17) | (0.20) | |
Interest Coverage |
13.00 | 7.81 | 10.77 | (42.08) | |
Research and Development Expense of Revenue |
17.33% | 19.97% | 19.71% | 22.61% | |
Selling, General and Administrative Expense of Revenue |
17.47% | 22.64% | 20.85% | 24.62% | |
Intangible Assets out of Total Assets |
0.45 | 0.43 | 0.44 | 0.45 | |
Share Based Compensation of Revenue |
2.96% | 2.90% | 3.13% | 2.96% | |
Graham Net Nets |
(0.14) | (0.12) | (0.08) | (0.15) | |
Graham Number |
50.32 | 52.94 | 56.12 | 0.00 | |
Earnings Yield |
5.87% | 5.58% | 5.32% | (2.06%) | |
Free Cash Flow Yield |
6.64% | 6.19% | 5.91% | 8.24% | |
Revenue per Share |
6.25 | 6.37 | 5.60 | 6.28 | |
Operating CF per Share |
3.30 | 2.67 | 2.05 | 2.87 | |
Capex per Share |
(0.12) | (0.16) | (0.09) | (0.11) | |
Free Cash Flow per Share |
3.19 | 2.51 | 1.95 | 2.76 | |
Cash per Share |
5.91 | 6.14 | 6.15 | 2.56 | |
Shareholders Equity per Share |
17.26 | 18.18 | 18.87 | 9.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.26 | 18.18 | 18.87 | 9.45 | |
Free Cash Flow |
3,961.00 | 3,122.00 | 2,427.00 | 3,433.00 | |
Working Capital |
5,576.00 | 6,529.00 | 9,165.00 | 2,925.00 | |
Capital Expenditures |
(147.00) | (205.00) | (117.00) | (140.00) | |
Net Current Asset Value |
(19,203.00) | (18,063.00) | (14,206.00) | (23,673.00) | |
EV/EBIT |
14.83 | 16.96 | 18.09 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
13.15 | 15.24 | 16.69 | 0.00 | |
| Other line items | |||||
Average Receivables |
4,841.00 | 4,666.50 | 4,564.50 | 4,918.00 | |
Average Payables |
855.50 | 774.00 | 691.00 | 628.00 | |
Average Inventory |
1,827.00 | 1,742.00 | 1,836.50 | 1,889.00 | |
Average Assets |
56,529.00 | 59,009.00 | 56,356.00 | 52,541.50 | |
Average Common Equity |
19,923.00 | 20,932.00 | 21,254.50 | 15,667.50 |
Columns are period end dates